Pomalidomide-based maintenance post-autologous hematopoietic cell transplantation in multiple myeloma: a case series
The treatment of multiple myeloma (MM) has undergone tremendous advances in the past two decades and particularly with the advent of two key drug classes: proteasome inhibitors and immunomodulatory drugs (IMiDs). The current dogma in MM treatment relies on continuous plasma cell–directed therapy starting with induction therapy, followed by consolidation (autologous hematopoietic cell transplantation (auto-HCT) in HCT-eligible patients) and maintenance treatment . Lenalidomide (len), an IMiD, is the only FDA-approved agent for maintenance therapy in MM and has demonstrated progression-free (PFS) and overall survival (OS) advantage in newly diagnosed patients . Pomalidomide (pom) is a highly potent third-generation IMiD that has been approved in the relapsed and refractory MM setting but has not been studied in the maintenance setting in a randomized fashion [3, 4].
Herein we report on the clinical characteristics and outcomes of patients treated with pom maintenance...
Compliance with ethical standards
All human studies have been approved by the appropriate ethics committee.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P, IFM 2009 Study (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376(14):1311–1320CrossRefGoogle Scholar
- 3.Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JFS (2014 Aug) Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28(8):1573–1585CrossRefGoogle Scholar